Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Human Antibody
100%
Immunotherapeutics
100%
Alphavirus
100%
Chikungunya Virus (CHIKV)
50%
Mayaro Virus
25%
Virus
25%
Viral Escape
25%
Eastern Equine Encephalitis Virus
25%
CHIKV Infection
12%
Efficacy Profile
12%
Broadly Protective
12%
Therapeutic mAb
12%
Protective Antibodies
12%
Viral Immunotherapy
12%
Animal Data
12%
Synergistic Interaction
12%
Venezuelan Equine Encephalitis Virus
12%
Human mAb
12%
Disease Model
12%
Antibody Therapy
12%
Conserved Epitopes
12%
Pharmacokinetic Profile
12%
B Domain
12%
Virus-like
12%
Large Mammals
12%
Two-component
12%
Non-neutralizing
12%
System Disease
12%
Musculoskeletal Disorders
12%
Nonhuman Primate
12%
Arthritis
12%
Mosquito Vectors
12%
Ross River Virus
12%
Arthritogenic
12%
Long Half-life
12%
E2 Glycoprotein
12%
Encephalitic
12%
In Vitro Properties
12%
Global Health Challenges
12%
Convalescent
12%
Large-scale Epidemics
12%
Immunology and Microbiology
Alphavirus
100%
Virus
37%
Infection
25%
Mayaro Virus
25%
In Vitro
25%
Infectious Disease
25%
Western Equine Encephalitis Virus
12%
Arthritis
12%
Virus Like Particle Vaccine
12%
Neutralization
12%
Glycoprotein
12%
Immunotherapy
12%
Ross River Virus
12%
Epitope
12%
Pharmacokinetics
12%
Eastern Equine Encephalitis Virus
12%
Venezuelan Equine Encephalitis Virus
12%
Musculoskeletal System
12%
Global Health
12%